GLOBAL (NORTH AMERICA, EUROPE, ASIA-PACIFIC, SOUTH AMERICA, MIDDLE EAST AND AFRICA) PACLITAXEL INJECTION MARKET 2018, FORECAST TO 2023

Jun 2018 133

Delivery of the Report will take 2-3 working days once order is placed.

Synopsis

Paclitaxel Injection is a kind of anti-cancer injection taking paclitaxel API as raw material. It is mainly used in breast cancer, ovarian cancer and other cancers.
Paclitaxel injection comes as a liquid to be given intravenously (into a vein) by a doctor or nurse in a hospital or clinic. It is usually given once every 3 weeks. When paclitaxel injection manufactured with polyoxyethylated castor oil is used to treat Kaposi's sarcoma, it may be given once every 2 or 3 weeks.


Scope of the Report:
This report focuses on the Paclitaxel Injection in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
In recent years, the growing population and increasing disease incidence of ovarian cancer, breast cancer and other cancers drive the global paclitaxel injection industry developing.

In the past five years from 2010-2014, global paclitaxel injection industry developed fast with a larger than 15% annual production growth rate. In China, due to the late start, the production growth rate is 12%~17%, which is a little lower than global average.

In the next few years, with the growing attention on women cancers from the whole society and much larger investment on R&D of paclitaxel injection, this industry will continue developing at a high speed. What’s more, because of the high gross profit of producing and selling paclitaxel injection, more and more investors will enter into this industry.

At present, the production of paclitaxel injection mainly concentrated in US, China and EU, the three regions produced about 77.30% of the global total products. Of those, US are the largest production region with a 42.69% of global production market share.

In the future, with the expanded capacity of paclitaxel injection, the manufacturers will face the high risk of price and gross margin decline.

The worldwide market for Paclitaxel Injection is expected to grow at a CAGR of roughly 11.0% over the next five years, will reach 3680 million US$ in 2023, from 2180 million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers
- Bristol-Myers Squibb
- Celgene Corporation
- Hospira
- Biological E.
- Taj Accura
- Khandelwal Laboratories
- Luye Pharma
- Beijing Youcare
- Beijing Union
- Haiyao
- Chuntch

Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
- Drug Strength
- Raw meterial Paclitaxel API source

Market Segment by Applications, can be divided into
- Ovarian cancer
- Breast cancer
- Cervical cancer
- Pancreatic cancer
- Other

There are 15 Chapters to deeply display the global Paclitaxel Injection market.
Chapter 1, to describe Paclitaxel Injection Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Paclitaxel Injection, with sales, revenue, and price of Paclitaxel Injection, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Paclitaxel Injection, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Paclitaxel Injection market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Paclitaxel Injection sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Table of Contents

Related reports :

(Aug 18)

L-Tryptophan is an amino acid. For many organisms (including humans), L-Tryptophan is an essential amino acid and cannot be synthesized by t...

(Aug 18)

Platinum-based antineoplastic drugs (informally called platins) are chemotherapeutic agents used to treat cancer. They are coordination comp...

(Aug 18)

Life science reagents are an integral part of the pharmaceutical, biotechnology, life science, and health care industries. These reagents ha...

(Aug 18)

Immunoglobulin Y (abbreviated as IgY) is a type of immunoglobulin which is the major antibody in bird, reptile, and lungfish blood. It is al...

(Aug 18)

Hypromellose acetate succinate is an enteric coating material which was first approved in Japan in 1987. As of January 2004, this pro...

(Aug 18)

Humira (adalimumab) is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation...

GLOBAL (NORTH AMERICA, EUROPE, ASIA-PACIFIC, SOUTH AMERICA, MIDDLE EAST AND AFRICA) PACLITAXEL INJECTION MARKET 2018, FORECAST TO 2023


Share this report on:

Subscription Option


Using our subscription option, you get access to Market Research Reports and industry data of Medicine and Pharmacy market as per your needs. Get the best of Medicine and Pharmacy research reports by utilizing your research budgets in an optimum way. Contact for details

Contact for reports

*

We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy